HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $64
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Akero Therapeutics (NASDAQ:AKRO) and raises the price target from $62 to $64.
June 07, 2023 | 10:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Akero Therapeutics and raises the price target from $62 to $64.
The news of HC Wainwright & Co. maintaining a Buy rating on Akero Therapeutics and raising the price target from $62 to $64 is positive for the company's stock. This indicates that the analyst has confidence in the company's growth potential and expects the stock price to rise in the short term. As a result, this news is likely to have a positive impact on AKRO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100